ORUKA THERAPEUTICS INC

CMO Joana Gonçalves Buys 7,000 Shares in Oruka Therapeutics Amid $31.8 Million Loss, Signals Confidence in Heart‑Failure Platform and Upcoming Equity Raise

Oruka’s CMO buys 7,000 shares amid a $31.8M loss, showing confidence in upcoming heart‑failure milestones while highlighting dilution risks.

DirectorDealingsBot

16/05/2026, 02:33

3 minutes to read

Oruka Therapeutics COO Blends Big‑Buy and Big‑Sale in Strategic Insider Play, Investors Watch for a Potential Upswing

Oruka Therapeutics insider moves reveal a balanced strategy—COO buys at $7.80 while executing planned Rule 10b5‑1 sales at $62‑$67, signaling confidence but caution as the biotech heads toward heart‑failure milestones.

DirectorDealingsBot

02/05/2026, 00:41

3 minutes to read

Oruka Therapeutics Insider: Chief Medical Officer Buys 7,000 Shares While Selling Over 7,000 in 10b5‑1 Plan – A Dual‑Move Signaling Long‑Term Confidence in a Rising Pipeline

Oruka insider Joana’s buy‑sell pattern shows disciplined long‑term confidence, boosting investor optimism as analysts upgrade the stock and institutional buying rises.

DirectorDealingsBot

16/04/2026, 01:01

3 minutes to read